(Q38259933)

1 September 2017

1 reference

title

Pharmacological interventions for preventing or delaying onset of type 2 diabetes mellitus (English)

1 reference

1 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

author name string

W Xu

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

M J Theodorakis

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

publication date

27 November 2014

1 reference

Diabetes, Obesity and Metabolism

1 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

page(s)

231-244

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study

5 June 2020

cites work

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

Prevention of type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise. The 6-year Malmö feasibility study

21 January 2018

1 reference

Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males.

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Many Americans have pre-diabetes and should be considered for metformin therapy

21 January 2018

1 reference

10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study

21 January 2018

1 reference

Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and β-cell function in TODAY.

21 January 2018

1 reference

Preservation of β-cell function: the key to diabetes prevention

21 January 2018

1 reference

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

Metabolic and hemodynamic effects of metformin and glibenclamide in normotensive NIDDM patients.

21 January 2018

1 reference

Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: a post-hoc analysis of the BIGPRO1 trial.

21 January 2018

1 reference

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

10-year follow-up of intensive glucose control in type 2 diabetes

21 January 2018

1 reference

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

21 January 2018

1 reference

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

21 January 2018

1 reference

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations

21 January 2018

1 reference

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

21 January 2018

1 reference

Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs

21 January 2018

1 reference

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation

21 January 2018

1 reference

Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance.

21 January 2018

1 reference

PPARγ signaling and metabolism: the good, the bad and the future

21 January 2018

1 reference

Thiazolidinediones : beyond glycemic control

21 January 2018

1 reference

Fat and beyond: the diverse biology of PPARgamma

21 January 2018

1 reference

TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus.

21 January 2018

1 reference

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

21 January 2018

1 reference

Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.

21 January 2018

1 reference

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control

21 January 2018

1 reference

The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients

21 January 2018

1 reference

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

21 January 2018

1 reference

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality

21 January 2018

1 reference

Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study

21 January 2018

1 reference

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

21 January 2018

1 reference

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

Skeletal consequences of thiazolidinedione therapy

21 January 2018

1 reference

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

Pharmacological agents that directly modulate insulin secretion

21 January 2018

1 reference

Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus

21 January 2018

1 reference

Repaglinide: a review of its use in type 2 diabetes mellitus

21 January 2018

1 reference

Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide

21 January 2018

1 reference

Meglitinide analogues: a review of clinical data focused on recent trials

21 January 2018

1 reference

Effect of nateglinide on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years

21 January 2018

1 reference

Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria

21 January 2018

1 reference

Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis

21 January 2018

1 reference

Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial

21 January 2018

1 reference

A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients

21 January 2018

1 reference

Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance

21 January 2018

1 reference

Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week

21 January 2018

1 reference

Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes

21 January 2018

1 reference

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis

21 January 2018

1 reference

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

21 January 2018

1 reference

Pharmacology, physiology, and mechanisms of incretin hormone action

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction

21 January 2018

1 reference

Sitagliptin improves beta-cell function in patients with acute coronary syndromes and newly diagnosed glucose abnormalities--the BEGAMI study.

21 January 2018

1 reference

Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance

21 January 2018

1 reference

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

Effects of exenatide vs. metformin on endothelial function in obese patients with pre-diabetes: a randomized trial

21 January 2018

1 reference

Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study

21 January 2018

1 reference

The safety of incretin-based therapies--review of the scientific evidence

21 January 2018

1 reference

Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus

21 January 2018

1 reference

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

21 January 2018

1 reference

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population

21 January 2018

1 reference

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy

21 January 2018

1 reference

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies

21 January 2018

1 reference

Effect of ramipril on the incidence of diabetes

21 January 2018

1 reference

Effect of valsartan on the incidence of diabetes and cardiovascular events

21 January 2018

1 reference

Angiotensin converting enzyme inhibitors for prevention of new-onset type 2 diabetes mellitus: a meta-analysis of 72,128 patients

21 January 2018

1 reference

Angiotensin receptor blockers for prevention of new-onset type 2 diabetes: a meta-analysis of 59,862 patients

21 January 2018

1 reference

The renin-angiotensin system and cancer: old dog, new tricks.

21 January 2018

1 reference

The renin-angiotensin system and malignancy

21 January 2018

1 reference

Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk

21 January 2018

1 reference

Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals

21 January 2018

1 reference

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

Anti-obesity drugs: a review about their effects and their safety

21 January 2018

1 reference

Orlistat-associated adverse effects and drug interactions: a critical review

21 January 2018

1 reference

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

21 January 2018

1 reference

Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study.

21 January 2018

1 reference

Impaired fasting glucose and impaired glucose tolerance: implications for care

21 January 2018

1 reference

Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms

21 January 2018

1 reference

Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study.

21 January 2018

1 reference

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

21 January 2018

1 reference

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

21 January 2018

1 reference

Metformin monotherapy for type 2 diabetes mellitus

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002966.PUB3

Identifiers

DOI

10.1111/DOM.12401

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25312701%20AND%20SRC:MED&resulttype=core&format=json

5 June 2020

1 reference